Shanghai Haoyuan Chemexpress Co., Ltd.

688131

CNE1000051J4

Pharmaceuticals

End-of-day quote Shanghai S.E. Other stock markets 23:00:00 06/06/2024 BST			5-day change	1st Jan Change
29.28 ^CNY	+3.57%		-2.72%	-43.76%

12:00am	Certain A Sharess of Shanghai Haoyuan Chemexpress Co., Ltd. are subject to a Lock-Up Agreement Ending on 8-JUN-2024.	CI
04-29	Shanghai Haoyuan Chemexpress Co., Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2024	CI

Shanghai Haoyuan Chemexpress Co., Ltd.(SHSE:688131) dropped from Shanghai Stock Exchange Health Care Sector Index

June 09, 2023 at 05:00 am

Shanghai Haoyuan Chemexpress Co., Ltd. has been removed

Latest news about Shanghai Haoyuan Chemexpress Co., Ltd.

Certain A Sharess of Shanghai Haoyuan Chemexpress Co., Ltd. are subject to a Lock-Up Agreement Ending on 8-JUN-2024.	07/06/2024	CI
Shanghai Haoyuan Chemexpress Co., Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2024	04-29	CI
Haoyuan Chemexpress to Issue 822 Million Yuan Worth of Convertible Bonds	03-25	MT
Haoyuan Chemexpress to Raise Subsidiary's Capital by 200 Million Yuan	03-25	MT
Shanghai Haoyuan Chemexpress Co., Ltd. Reports Earnings Results for the Full Year Ended December 31, 2023	02-23	CI
Shanghai Haoyuan Chemexpress Co., Ltd. Reports Earnings Results for the Nine Months Ended September 30, 2023	30/10/23	CI
Shanghai Haoyuan Chemexpress Co., Ltd.(XSSC:688131) added to S&P Global BMI Index	18/09/23	CI
Shanghai Haoyuan Chemexpress Co., Ltd. Reports Earnings Results for the Half Year Ended June 30, 2023	28/08/23	CI
Shanghai Haoyuan Chemexpress Shareholders Plan to Unload Company's Stakes	20/07/23	CI
Shanghai Haoyuan Chemexpress Co., Ltd.(SHSE:688131) dropped from Shanghai Stock Exchange Health Care Sector Index	09/06/23	CI
Shanghai Haoyuan Chemexpress Co., Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2023	28/04/23	CI
Haoyuan Chemexpress to Build Drug Center for 500 Million Yuan	11/04/23	MT
Haoyuan Chemexpress Logs 1.4% Rise in 2022 Profit	28/02/23	MT
Shanghai Haoyuan Chemexpress Co., Ltd. Reports Earnings Results for the Full Year Ended December 31, 2022	26/02/23	CI
Haoyuan Chemexpress Raising 50 Million Yuan From Controlling Shareholder to Buy Local Drugmaker	13/01/23	MT
Shanghai Haoyuan Chemexpress Co., Ltd. announced that it has received CNY 49.999962 million in funding from Shanghai Anxu Information Technology Co., Ltd., Shanghai Yuanmeng Enterprise Management Consulting Partnership (Limited Partnership), Ningbo Jiusheng Innovation Pharmaceutical Technology Co., Ltd, Shanghai Yuanli Enterprise Management Partnership	27/12/22	CI
Shanghai Haoyuan Chemexpress Co., Ltd. completed the acquisition of 2Y-Chem, Ltd. from Ningbo Jiusheng Innovative Pharmaceutical Technology Co., Ltd., Qidong Yuanli Enterprise Management Consulting Partnership (Limited Partnership), Shanghai Yuanmeng Enterprise Management Consulting Partnership (Limited Partnership) and WANG YUAN.	23/12/22	CI
Shanghai Haoyuan Chemexpress Co., Ltd.(SHSE:688131) added to Shanghai Stock Exchange Health Care Sector Index	12/12/22	CI
Shanghai Haoyuan Chemexpress Co., Ltd. Reports Earnings Results for the Nine Months Ended September 30, 2022	27/10/22	CI
Shanghai Haoyuan Chemexpress Co., Ltd. Reports Earnings Results for the Half Year Ended June 30, 2022	25/08/22	CI
Shanghai Haoyuan Chemexpress Co., Ltd.(SHSE:688131) added to Shanghai Stock Exchange A Share Index	08/06/22	CI
Shanghai Haoyuan Chemexpress Co., Ltd.(SHSE:688131) added to Shanghai Stock Exchange Composite Index	08/06/22	CI
Certain A Shares of Shanghai Haoyuan Chemexpress Co., Ltd. are subject to a Lock-Up Agreement Ending on 8-JUN-2022.	07/06/22	CI
Shanghai Haoyuan Chemexpress Co., Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2022	26/04/22	CI
Shanghai Haoyuan Chemexpress Co., Ltd. agreed to acquire 2Y-Chem, Ltd. from Ningbo Jiusheng Innovative Pharmaceutical Technology Co., Ltd., Qidong Yuanli Enterprise Management Consulting Partnership (Limited Partnership), Shanghai Yuanmeng Enterprise Management Consulting Partnership (Limited Partnership) and WANG YUAN for CNY 410 million.	04/03/22	CI

Chart Shanghai Haoyuan Chemexpress Co., Ltd.

Duration

Period

Chart Shanghai Haoyuan Chemexpress Co., Ltd.

More charts

Shanghai Haoyuan Chemexpress Co Ltd is a China-based company mainly engaged in the research and development, production and sales of small molecule drugs. The Company's main products include molecular building blocks and tool compounds. The Company's products also include active pharmaceutical ingredients (APIs) and intermediates. The Company also provides related services such as contract research organization (CRO) service. The Company's molecular building blocks and tool compounds are applied in all stages of the drug discovery process. The Company distributes its products in domestic market and to overseas markets.

Sector

Pharmaceuticals

Calendar

21/08/2024 - Q2 2024 Earnings Release (Projected)

More about the company

Income Statement Evolution

More financial data

Ratings for Shanghai Haoyuan Chemexpress Co., Ltd.

Trading Rating

Investor Rating

ESG Refinitiv

More Ratings

Analysts' Consensus

Sell

Buy

Mean consensus

BUY

Number of Analysts

Last Close Price

29.28 CNY

Average target price

44 CNY

Spread / Average Target

+50.27%

Consensus

EPS Revisions

Estimates Revisions

Annual profits - Rate of surprise

Company calendar

Sector Biopharmaceuticals

	1st Jan change	Capi.
SHANGHAI HAOYUAN CHEMEXPRESS CO., LTD.	-43.76%	608M
CSL LIMITED	+0.82%	91.94B
SAMSUNG BIOLOGICS CO.,LTD.	-1.32%	38.74B
BIOGEN INC.	-12.88%	32.82B
UCB	+64.77%	26.66B
BIOMARIN PHARMACEUTICAL INC.	-16.31%	15.32B
INCYTE CORPORATION	-5.78%	13.3B
BEIJING WANTAI BIOLOGICAL PHARMACY ENTERPRISE CO., LTD.	-11.38%	11.65B
CHONGQING ZHIFEI BIOLOGICAL PRODUCTS CO., LTD.	-49.84%	10.12B
SWEDISH ORPHAN BIOVITRUM AB	+5.24%	9.06B

Biopharmaceuticals